Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

KAI initiates second phase II trial for KAI-1678 in neuropathic pain

April 2, 2009

Dexmedetomidine shows favorable pharmacokinetics for long-term sedation in renal failure patients

April 2, 2009

Acorda Therapeutics receives FDA refuse to file letter for Fampridine-SR NDA

April 1, 2009

Shire and GlaxoSmithKline to co-promote Vyvanse for adult ADHD

April 1, 2009

Sepracor submits NDA to FDA for Stedesa as adjunctive epilepsy treatment

April 1, 2009

Newron randomizes first patients in phase IIb/III ralfinamide study in pain

April 1, 2009

ExonHit expands neurological research activities to include epilepsy

April 1, 2009

Roche presents novel TAAR1 ligands

April 1, 2009

5-HT6 antagonist AVN-322 deemed a candidate for neurodegenerative diseases

April 1, 2009

Novel metabotropic glutamate receptor agonists display antiparkinsonian effects in vivo

April 1, 2009

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...